Target and Technology

SGN-CD19B is an antibody-drug conjugate (ADC) targeted to CD19, a protein widely found on B-cell hematologic malignancies. It uses our proprietary ADC technology, which attaches the anti-CD19 antibody to two molecules of a highly potent DNA crosslinking agent called a PBD (pyrrolobenzodiazepine) dimer using a stable linker.

ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.

Clinical Development Status

  • Phase 1 trial evaluating safety and antitumor activity of SGN-CD19B in patients with B-cell non-Hodgkin lymphoma (NHL)

Proposed Mechanism of Action

PBD_generic_release_19B_r6c_flat.jpg

SGN-CD19B is an investigational agent, and its safety and efficacy have not yet been established.